SEC Form 4 · accession 0001415889-19-000144
CELGENE CORP /DE/ · CELG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James J Loughlin
Director
Period of report
Feb 7, 2019
Accepted (ET)
Feb 11, 2019 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816284
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 7, 2019 | M | 24,666 | $22.47 | A | 62,102 | D | |
| Common StockF1 | Feb 7, 2019 | S | 23,466 | $87.289 | D | 38,636 | D | |
| Common StockF2 | holding | — | — | — | 1,800 | I | Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4,F3 | $22.47 | Feb 7, 2019 | M | 24,666 | D | — | Jun 17, 2019 | Common Stock | 24,666 | 0 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $87.28 to $87.30, inclusive. The reporting person undertakes to provide Celgene Corporation (the "Company"), any security holder of the Company or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
- F2The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- F3The option was fully exercisable.
- F4The option was issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan).